Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Malignant Ureter Neoplasm

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Malignant Ureter Neoplasm

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 14 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
      source wording
      Source null

      Study evidence for this setting

      9 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00661609 · Registry condition search · Scope: narrower

      A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

      5 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00749892 · Registry condition search · Scope: narrower

      Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

      2 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00942331 · Registry condition search · Scope: narrower

      Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

      4 outcome links · 2 safety-group records · 2 quality-of-life measures

      →

      NCT01326871 · Registry condition search · Scope: narrower

      A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

      3 outcome links · 3 safety-group records · 0 quality-of-life measures

      →

      NCT02122172 · Registry condition search · Scope: narrower

      Afatinib in Advanced Refractory Urothelial Cancer

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT02178241 · Registry condition search · Scope: narrower

      Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

      4 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT02300610 · Registry condition search · Scope: narrower

      Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

      4 outcome links · 3 safety-group records · 0 quality-of-life measures

      →

      NCT03513952 · Registry condition search · Scope: narrower

      Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

      6 outcome links · 3 safety-group records · 0 quality-of-life measures

      →

      NCT03617913 · Registry condition search · Scope: narrower

      Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

      6 outcome links · 1 safety-group records · 2 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-malignant-ureter-neoplasm
        binding id
        ncit-C7543
        source collection
        ncit-concept
        source key
        C7543
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice